What’s your equity market outlook in the near-to-medium term? Do you see more downside risk or can the market regain some lost ground?
Given the macro-economic headwinds, the markets are likely to remain in a range in the near-term. At the same time, given the recent correction, the downside seems limited as valuations at 13.5x FY14e earnings are fairly supportive. Going ahead, the market direction will be dependent on pace of the economic reforms and the recovery in the investment demand.
Do you think Indian economic scenario will improve in 2013 and also get a bit of a tailwind from the global economic cycle?
If the reforms momentum continues to gain traction and the macro data points improve from here on, there is a case for the markets to move up. Most central banks around the world are continuing to follow an easy liquidity policy, which is positive for most asset classes including equities. However, given the current macro head winds in India, markets are likely to remain in a range in the near-term.
How do you see the FII flows panning out going ahead?
After seeing significant flows in the past few months, FII flows seems to be taking a breather now given the sharp run up in the markets. Further, any development like the one seen in Cyprus can cause risk aversion in the mind of the investors and could impact the flows towards the emerging markets.
Did the recent small- and mid-cap carnage impact your portfolio?
Mid-caps / Small-caps are relatively more volatile as compared to large caps. They also have a relatively higher risk/return profile. It is very difficult to generalise the movement of these stocks given the fact that most mid-cap stocks have gone up a lot in the past few months and are now correcting. Our investment philosophy and the strict risk control measures ensure that we buy only high quality companies in our portfolios and hence the impact has been limited.
To which sectors do you have maximum exposure?
Given the run-up in the markets over the past few months, we have rebalanced our portfolios towards defensives. We have increased our exposure to information technology (IT) and pharmaceuticals given their strong growth prospects. In addition, any further depreciation in the Rupee is likely to benefit these sectors. Thus, these two being export driven sectors appear a good space to be in. Overall, we believe there is possibility of divergence of performance within sectors and stock selection will be the key to performance.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
